Orthofix Medical Inc. (OFIX)
Chart Events
Performance Outlook
| Previous Close | 22.74 |
| Open | 22.83 |
| Bid | 8.92 x 800 |
| Ask | 35.64 x 900 |
| Day's Range | 22.13 - 22.78 |
| 52 Week Range | 21.66 - 43.30 |
| Volume | |
| Avg. Volume | 97,059 |
| Market Cap | 439.925M |
| Beta (5Y Monthly) | 1.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.76 |
| Earnings Date | Apr 28, 2022 - May 02, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 46.83 |
- Zacks
Orthofix (OFIX) Beats Q2 Earnings and Revenue Estimates
Orthofix (OFIX) delivered earnings and revenue surprises of 14.29% and 0.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Orthofix Reports Second Quarter 2022 Results
LEWISVILLE, Texas, August 05, 2022--Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the quarter ended June 30, 2022. Net sales were $118.1 million, earnings per share ("EPS") was $0.12, and adjusted EPS was $0.08.
- Business Wire
Orthofix Medical and CGBio Announce Strategic Partnership Agreement for Novosis rhBMP-2 Bone Graft Solutions
LEWISVILLE, Texas, August 02, 2022--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced a strategic partnership agreement with CGBio, a developer of innovative, synthetic bone grafts currently used clinically in Asia for spine, orthopedic, trauma and dental applications. The two companies will work together for clinical development and commercialization of Novosis™ recombinant human bone morphogenetic protein-2 (rhBMP-2) bone g
